|
1
|
Hamamoto Y: Complications in advanced or
recurrent gastric cancer patients with peritoneal metastasis during
and after palliative systemic chemotherapy. Mol Clin Oncol.
3:539–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN, 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Price TJ, Shapiro JD, Segelov E, Karapetis
CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK and Tebbutt NC:
Management of advanced gastric cancer. Expert Rev Gastroenterol
Hepatol. 6:199–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Latchman Y, Wood CR, Chernova T, Chaudhary
D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al:
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2:261–268. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng H, Liu X, Zhang J, Rice SJ, Wagman
M, Kong Y, Zhu L, Zhu J, Joshi M and Belani CP: Expression of PD-1
on CD4+ T cells in peripheral blood associates with poor clinical
outcome in non-small cell lung cancer. Oncotarget. 7:56233–56240.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Komura T, Sakai Y, Harada K, Kawaguchi K,
Takabatake H, Kitagawa H, Wada T, Honda M, Ohta T, Nakanuma Y and
Kaneko S: Inflammatory features of pancreatic cancer highlighted by
monocytes/macrophages and CD4+ T cells with clinical impact. Cancer
Sci. 106:672–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibutani M, Maeda K, Nagahara H, Fukuoka
T, Nakao S, Matsutani S, Hirakawa K and Ohira M: The prognostic
significance of the tumor-infiltrating programmed cell
death-1+ to CD8+ lymphocyte ratio in patients
with colorectal cancer. Anticancer Res. 37:4165–4172.
2017.PubMed/NCBI
|
|
11
|
Baas W, Gershburg S, Dynda D, Delfino K,
Robinson K, Nie D, Yearley JH and Alanee S: Immune characterization
of the programmed death receptor pathway in high risk prostate
cancer. Clin Genitourin Cancer. 15:577–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan J, Zhang J, Zhu Y, Li N, Tian T, Li
Y, Li Y, Li Z, Lai Y, Gao J and Shen L: Programmed death-ligand-1
expression in advanced gastric cancer detected with RNA in situ
hybridization and its clinical significance. Oncotarget.
7:39671–39679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eto S, Yoshikawa K, Nishi M, Higashijima
J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T and Shimada
M: Programmed cell death protein 1 expression is an independent
prognostic factor in gastric cancer after curative resection.
Gastric Cancer. 19:466–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vali B, Jones RB, Sakhdari A, Sheth PM,
Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, Saeed S, et al:
HCV-specific T cells in HCV/HIV co-infection show elevated
frequencies of dual Tim-3/PD-1 expression that correlate with liver
disease progression. Eur J Immunol. 40:2493–2505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lauwers GY CF and Graham DY: Curado MP
tumours of the stomach. WHO classification of tumours of the
digestive system Bosman FT CF. Hruban RH and Theise ND: 48–59.
2010.
|
|
16
|
Aldarouish M and Wang C: Trends and
advances in tumor immunology and lung cancer immunotherapy. J Exp
Clin Cancer Res. 35:1572016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dougan M and Dranoff G: Immune therapy for
cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sharon E, Streicher H, Goncalves P and
Chen HX: Immune checkpoint inhibitors in clinical trials. Chin J
Cancer. 33:434–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brahmer JR, Hammers H and Lipson EJ:
Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future
Oncol. 11:1307–1326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Böger C, Behrens HM, Mathiak M, Krüger S,
Kalthoff H and Röcken C: PD-L1 is an independent prognostic
predictor in gastric cancer of Western patients. Oncotarget.
7:24269–24283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang W, Chen Y, Sheng J, Zhou T, Zhang Y,
Zhan J, Liu L, Huang J, Peng P and Zhang L: Association between
PD-L1 expression on tumour-infiltrating lymphocytes and overall
survival in patients with gastric cancer. J Cancer. 8:1579–1585.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito R, Abe H, Kunita A, Yamashita H,
Seto Y and Fukayama M: Overexpression and gene amplification of
PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr
virus-associated gastric cancer: The prognostic implications. Mod
Pathol. 30:427–439. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wen T, Wang Z, Li Y, Li Z, Che X, Fan Y,
Wang S, Qu J, Yang X, Hou K, et al: A four-factor immunoscore
system that predicts clinical outcome for stage II/III gastric
cancer. Cancer Immunol Res. 5:524–534. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X,
Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1)
expression on gastric cancer and its relationship with
clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091.
2015.PubMed/NCBI
|
|
28
|
Zhang M, Dong Y, Liu H, Wang Y, Zhao S,
Xuan Q, Wang Y and Zhang Q: The clinicopathological and prognostic
significance of PD-L1 expression in gastric cancer: A meta-analysis
of 10 studies with 1,901 patients. Sci Rep. 6:379332016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T,
Wang Q and Jiang J: PD-1 and PD-L1 co-expression predicts favorable
prognosis in gastric cancer. Oncotarget. 8:64066–64082.
2017.PubMed/NCBI
|
|
30
|
Brown JA, Dorfman DM, Ma FR, Sullivan EL,
Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of
programmed death-1 ligands on dendritic cells enhances T cell
activation and cytokine production. J Immunol. 170:1257–1266. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong H and Chen L: B7-H1 pathway and its
role in the evasion of tumor immunity. J Mol Med (Berl).
81:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
